---
title: "Xarelto (rivaroxaban) in nonvalvular atrial fibrillation: Real-world evidence questions"
description: "Real-world evidence questions on Xarelto (rivaroxaban) in nonvalvular atrial fibrillation, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Xarelto vs Eliquis: what did a real-world study in Israel show? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/real-world-evidence"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Xarelto (rivaroxaban) in nonvalvular atrial fibrillation: Real-world evidence questions

Manufacturer: Janssen Pharmaceuticals, Inc.  
Prescribing information: [Xarelto](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf)

Questions that apply to every indication of Xarelto are on [Xarelto (rivaroxaban), all indications](https://www.evicenter.com/medical-information/xarelto).

## Real-world evidence

<a id="xarelto-real-world-vs-eliquis"></a>

### Xarelto vs Eliquis: what did a real-world study in Israel show?

> “Talmor-Barkan et al: a head-to-head nationwide (in Israel), retrospective, observational study of DOAC treatment in NVAF, published in the European Heart Journal - Cardiovascular Pharmacotherapy and not funded by industry”

Source: [XARELTO: Nonvalvular Atrial Fibrillation (NVAF), captured 2026-11-13](https://www.xareltohcp.com/nonvalvular-atrial-fibrillation/#:~:text=Talmor%2DBarkan%20et%20al%3A%20a%20head%2Dto%2Dhead,and%20not%20funded%20by%20industry)

> “XARELTO® was associated with an ischemic stroke rate of 49.3 vs 55.8 for Eliquis® per 1000 person-years”

Source: [XARELTO: Nonvalvular Atrial Fibrillation (NVAF), captured 2026-11-13](https://www.xareltohcp.com/nonvalvular-atrial-fibrillation/#:~:text=XARELTO%C2%AE%20was%20associated%20with%20an,for%20Eliquis%C2%AE%20per%201000%20person%2Dyears)

> “‡The order of the pairwise comparisons was not prespecified, and no adjustments for multiplicity were made.”

Source: [XARELTO: Nonvalvular Atrial Fibrillation (NVAF), captured 2026-11-13](https://www.xareltohcp.com/nonvalvular-atrial-fibrillation/#:~:text=%E2%80%A1The%20order%20of%20the%20pairwise,adjustments%20for%20multiplicity%20were%20made.)

> “Overall bleeding
> XARELTO®: n=15,654
> Eliquis®: n=15,631
> 	No differences were observed in overall bleeding rates	
> 1.02
> (0.92-1.13)
>
> Intracranial hemorrhage
> XARELTO®: n=15,654
> Eliquis®: n=15,633
> 	XARELTO® was associated with an ICH rate of 9.4 vs 11.6 for Eliquis® per 1000 person-years	
> 0.86
> (0.74-1.00)
>
> Gastrointestinal bleeding
> XARELTO®: n=15,668
> Eliquis®: n=15,667
> 	XARELTO® was associated with a GI bleeding rate of 9.5 vs 7.9 for Eliquis® per 1000 person-years	
> 1.22
> (1.03-1.44)
>
> Bleeding, other
> XARELTO®: n=15,668
> Eliquis®: n=15,667
> 	No differences were observed in other bleeding rates	
> 1.18
> (0.94-1.48)”

Source: [XARELTO: Nonvalvular Atrial Fibrillation (NVAF), captured 2026-11-13](https://www.xareltohcp.com/nonvalvular-atrial-fibrillation/#:~:text=Overall%20bleeding,%280.94%2D1.48%29)

> “†The order of the pairwise comparisons was not prespecified, and no adjustments for multiplicity were made.”

Source: [XARELTO: Nonvalvular Atrial Fibrillation (NVAF), captured 2026-11-13](https://www.xareltohcp.com/nonvalvular-atrial-fibrillation/#:~:text=%E2%80%A0The%20order%20of%20the%20pairwise,adjustments%20for%20multiplicity%20were%20made.)

> “Note: Due to differences in study design, patient populations, definitions of outcomes, and data collection methods, the results of real-world studies are not intended for direct comparisons with clinical trials.”

Source: [XARELTO: Nonvalvular Atrial Fibrillation (NVAF), captured 2026-11-13](https://www.xareltohcp.com/nonvalvular-atrial-fibrillation/#:~:text=Note%3A%20Due%20to%20differences%20in,direct%20comparisons%20with%20clinical%20trials.)

Note: This is a retrospective observational comparison of two cohorts in Israel. The first multiplicity footnote belongs to the effectiveness result and the second to the bleeding table. The page text gives no hazard ratio or confidence interval for ischemic stroke. In the bleeding table each row gives the outcome, the number of patients in each cohort, the event-rate statement, and the hazard ratio (95% CI) for XARELTO vs Eliquis. The page does not state the doses either cohort received. The Eliquis questions in this collection quote observational analyses from the Eliquis HCP site with results in the other direction, and the Eliquis statement that there are currently no results from clinical trials comparing the two products for stroke risk reduction in NVAF.

## Related pages
- [Medical information: Xarelto (rivaroxaban): Nonvalvular atrial fibrillation](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation)
- [Indication](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/safety)
- [Specific populations](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/guidelines)
